Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk: A Randomized, Double-Blind, Placebo-Controlled Trial

Study Questions:

What is the efficacy and safety of mipomersen for reducing atherogenic lipids/lipoproteins in persons with or at high risk for coronary heart disease (CHD)?